adyn
adyn offers an at-home test that analyzes hormone levels and genetic risk to help individuals select birth control options with fewer side effects. The service includes a virtual care visit with a licensed medical provider and the option to fulfill a personalized prescription. Its mission is to advance inclusive scientific discovery and personalized medicine for under-researched health conditions.
Facts
- HQ
- Seattle, US
- Sectors
- Biotechnology Research
- Founded
- 2020
- Type
- Corporation Seattle business license
- Employees
- 9
- Registered name
- adyn Inc Seattle business license
- Stage
- Seed
- Founders
- Elizabeth Ruzzo
Is this your organization? Claim it
adyn CEO Elizabeth Ruzzo launches genetic-and-hormone test this fall to predict birth-control side effects
Elizabeth Ruzzo, founder and CEO of Seattle startup adyn, is launching a fall test that analyzes genetic and hormone data to predict birth-control side effects and reduce trial-and-error prescribing. She aims to make scientific discovery more inclusive by addressing biases in medical research and offering users the option to opt into anonymous research.
adyn raises $2.5M seed round from Lux Capital, M13 and investors including 23andMe CEO to launch birth-control test
Seattle startup adyn raised a $2.5 million seed round co-led by Lux Capital and M13 to launch an at-home birth control optimization test later this year, and currently has a waitlist for early access. The test analyzes hormone levels to identify birth-control–related side effects and pairs personalized results with telemedicine and prescription delivery.
People
-
Elizabeth Ruzzo Founder, CEO